Liptruzet Side Effects

Generic name: atorvastatin / ezetimibe

Medically reviewed by Drugs.com. Last updated on Jan 28, 2024.

Note: This document contains side effect information about atorvastatin / ezetimibe. Some dosage forms listed on this page may not apply to the brand name Liptruzet.

Applies to atorvastatin / ezetimibe: oral tablet.

Get emergency medical help if you have any of these signs of an allergic reaction while taking atorvastatin / ezetimibe: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

In rare cases, atorvastatin can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have unexplained muscle pain, tenderness, or weakness especially if you also have fever, unusual tiredness, and dark colored urine.

Stop using this medicine and call your doctor at once if you have:

• nausea, upper stomach pain, loss of appetite;

• itching, unusual tiredness; or

• dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Common side effects may include:

• mild muscle pain;

• stomach pain, diarrhea; or

• joint pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to atorvastatin / ezetimibe: oral tablet.

General

The more commonly reported adverse reactions have included increased ALT, increased AST, and musculoskeletal pain.^[Ref]

Hepatic

Common (1% to 10%): ALT increased (5%), AST increased (4%)

Postmarketing reports: Hepatitis, cholelithiasis, cholecystitis, fatal and nonfatal hepatic failure^[Ref]

Musculoskeletal

Common (1% to 10%): Musculoskeletal pain (3.8 to 4%), arthralgia (3 to 6.9%), pain in extremity (2.7 to 6%), myalgia (3.5%), muscle spasms (3%), muscle weakness (2%)

Postmarketing reports: Myopathy/rhabdomyolysis, necrotizing myopathy (rarely), injury, poisoning and procedural complication, tendon rupture, myositis^[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea (4.1 to 6.8%), abdominal pain (3%), nausea (3 to 4%), dyspepsia (4.7%)^[Ref]

Nervous system

Common (1% to 10%): Dizziness (2 to 6%), insomnia (3%), fatigue (2.4%)

Postmarketing reports: Headache, paraesthesia, peripheral neuropathy, amnesia, memory impairment, confusion, depression, dizziness^[Ref]

Metabolic

Common (1% to 10%): Hyperkalemia (2%)^[Ref]

Endocrine

Common (1% to 10%): Hot flushes (2%)^[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection (5.7%)^[Ref]

Hematologic

Postmarketing reports: Thrombocytopenia, elevated creatine phosphokinase^[Ref]

Hypersensitivity

Postmarketing reports: Anaphylaxis, hypersensitivity reactions^[Ref]

Immunologic

Common (1% to 10%): Influenza (2%)^[Ref]

Respiratory

Common (1% to 10%): Coughing (2 to 3%), bronchitis (2%), sinusitis (2 to 2.8%), upper respiratory tract infection (4.3%), nasopharyngitis (up to 8.3%), pharyngolaryngeal pain (up to 2.3%)

Postmarketing reports: Interstitial lung disease^[Ref]

Other

Postmarketing reports: Fatigue

Dermatologic

Postmarketing reports: Angioedema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rash, urticaria^[Ref]

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer